线粒体TXNRD2和ME3遗传风险评分与特定原发性开角型青光眼表型相关
这项横断面研究纳入2617例原发性开角型青光眼(POAG)患者和2634名对照,构建TXNRD2、ME3及联合遗传风险评分(GRS)。TXNRD2+ME3 GRS最高十分位者POAG风险高于最低十分位(OR 1.79,95%CI 1.39-2.30,P<0.001);TXNRD2 GRS最高1%患者平均最高治疗眼压高于最低1%,ME3及联合GRS最高1%患者旁中心视野缺损患病率高于最低1%。
要点
- TXNRD2+ME3 GRS最高十分位者POAG风险约为最低十分位的1.79倍(95%CI 1.39-2.30,P<0.001)。
- TXNRD2 GRS最高1%的POAG患者平均最高治疗眼压19.9 mmHg,高于最低1%的15.6 mmHg(校正P=0.03)。
- ME3 GRS最高1%者旁中心视野缺损患病率72.7%,高于最低1%的14.3%(校正P=0.03)。
核心结论
- TXNRD2和ME3 GRS较高的POAG患者表现出更高的治疗眼压和更普遍的旁中心视野缺损。
- 作者认为需要开展功能研究探索这些变异如何影响青光眼患者的线粒体功能。
研究设计与样本
- 横断面研究,纳入来自NEIGHBORHOOD联盟的2617例POAG患者和2634名对照。
- 利用GWAS数据识别TXNRD2和ME3位点所有POAG相关SNP(P<0.05),校正连锁不平衡后选取20个TXNRD2和24个ME3 SNP。
- 使用Gene-Tissue Expression数据库分析SNP效应量与基因表达水平的相关性。
- 以TXNRD2、ME3及两者联合风险等位基因的未加权和构建每个个体的GRS,计算按十分位分组的年龄和性别校正POAG诊断OR。
- 比较各GRS最高1%、5%、10%与最低1%、5%、10%的POAG患者临床特征。
主要发现
- SNP效应量较大与TXNRD2表达水平较高(r=0.95)及ME3表达水平较低(r=-0.97)强相关,两者P<0.05。
- TXNRD2+ME3 GRS第10十分位个体POAG诊断风险最高,与第1十分位相比OR为1.79(95%CI 1.39-2.30,P<0.001)。
- TXNRD2 GRS最高1%的POAG患者平均最高治疗眼压为19.9 mmHg,最低1%为15.6 mmHg(校正P=0.03)。
- ME3 GRS最高1%的POAG患者旁中心视野缺损患病率为72.7%,最低1%为14.3%(校正P=0.03)。
- TXNRD2+ME3 GRS最高1%的POAG患者旁中心视野缺损患病率为88.9%,最低1%为33.3%(校正P=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要开展功能研究探索这些变异如何影响青光眼患者的线粒体功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Genetic variants in regions that include the mitochondrial genes thioredoxin reductase 2 (TXNRD2) and malic enzyme 3 (ME3) are associated with primary open-angle glaucoma (POAG) in genome-wide association studies (GWASs). To assess their clinical impact, we investigated whether TXNRD2 and ME3 genetic risk scores (GRSs) are associated with specific glaucoma phenotypes. DESIGN: Cross-sectional study. PARTICIPANTS: A total of 2617 patients with POAG and 2634 control participants from the National Eye Institute Glaucoma Human Genetics Collaboration Hereditable Overall Operational Database (NEIGHBORHOOD) consortium. METHODS: All POAG-associated single nucleotide polymorphisms (SNPs) in the TXNRD2 and ME3 loci were identified using GWAS data (P < 0.05). Of these, 20 TXNRD2 and 24 ME3 SNPs were selected after adjusting for linkage disequilibrium. The correlation between SNP effect size and gene expression levels was investigated using the Gene-Tissue Expression database. Genetic risk scores were constructed for each individual using the unweighted sum of TXNRD2, ME3, and TXNRD2 + ME3 combined risk alleles. Age- and sex-adjusted odds ratios (ORs) for POAG diagnosis were calculated per decile for each GRS. Additionally, the clinical features of patients with POAG in the top 1%, 5%, and 10% of each GRS were compared with those in the bottom 1%, 5%, and 10%, respectively. MAIN OUTCOME MEASURES: Primary open-angle glaucoma OR per GRS decile, maximum treated intraocular pressure (IOP), and prevalence of paracentral visual field loss among patients with POAG with high versus low GRSs. RESULTS: A larger SNP effect size strongly correlated with higher TXNRD2 and lower ME3 expression levels (r = 0.95 and r = -0.97, respectively; P < 0.05 for both). Individuals in decile 10 of the TXNRD2 + ME3 GRS had the highest odds of POAG diagnosis (OR, 1.79 compared with decile 1; 95% confidence interval, 1.39-2.30; P < 0.001). Patients with POAG in the top 1% of the TXNRD2 GRS showed higher mean maximum treated IOP compared with the bottom 1% (19.9 mmHg vs. 15.6 mmHg; adjusted P = 0.03). Patients with POAG in the top 1% of the ME3 and TXNRD2 + ME3 GRS showed a higher prevalence of paracentral field loss than the bottom 1% (72.7% vs. 14.3% for ME3 GRS and 88.9% vs. 33.3% for TXNRD2+ME3 GRS; adjusted P = 0.03 for both). CONCLUSIONS: Patients with POAG with higher TXNRD2 and ME3 GRSs showed higher treated IOP and a greater prevalence of paracentral field loss. Functional studies exploring how these variants impact mitochondrial function in patients with glaucoma are warranted. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Aboobakar IF, Kinzy TG, Zhao Y, et al. Mitochondrial TXNRD2 and ME3 Genetic Risk Scores Are Associated with Specific Primary Open-Angle Glaucoma Phenotypes. Ophthalmology. 2023. PMID: 36813040. doi:10.1016/j.ophtha.2023.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。